Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: A randomized dose-ranging pivotal study

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1340-1346

  Hesketh, Paul J ^a   Rossi, G ^b   Rizzi, G ^b   Palmas, M ^b   Alyasova, A ^c   Bondarenko, I ^d   Lisyanskaya, A ^e   Gralla, R J ^f  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b HELSINN HEALTHCARE SA   (Switzerland)

^c PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^d Dnipropetrovsk State Medical Academy   (Ukraine)

^e City Oncology Dispensary   (Russian Federation)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CINV; Highly emetogenic; NEPA; Netupitant; Neurokinin 1 receptor antagonist; Palonosetron

Indexed keywords

ALANINE AMINOTRANSFERASE; APREPITANT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; NETUPITANT; ONDANSETRON; PALONOSETRON; PLACEBO; ANTINEOPLASTIC AGENT; DRUG COMBINATION; ISOQUINOLINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRADYCARDIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECG ABNORMALITY; EXPLORATORY RESEARCH; FEMALE; HEADACHE; HEART BUNDLE BRANCH BLOCK; HICCUP; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; NAUSEA; ORAL DRUG ADMINISTRATION; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PYRIDINES; QUINUCLIDINES; VOMITING;

EID: 84903748544     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu110     Document Type: Article

References (11)

1. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22: 30-38.
2. Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012; 684: 1-7.
3. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
4. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial. Lancet Oncol 2009; 10: 115-124.
5. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
6. Stathis M, Pietra C, Rojas C et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 2012; 689: 25-30.
7. Spinelli T, Calcagnile S, Giuliano C. et al. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 2014; 54(1): 97-108.
8. Grunberg S, Voisin D, Zufferli M et al. Oral palonosetron is as effective as intravenous palonosetron: a phase 3 dose ranging trial in patients receiving moderately emetogenic chemotherapy. Eur J Cancer 2007; 5 (Suppl 4): abstr 1143, p. 155.
9. Boccia R, Grunberg S, Franco-Gonzales E et al. Efficacy of oral palonosetron compared to intravenous palonosetron for prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 2013; 21: 1453-1460.
10. Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009; 69: 1853-1878.
11. Grunberg SM, Warr D, Gralla RJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer 2011; 19(Suppl 1): S43-S47.